TY - JOUR
T1 - Beyond HbA1c and Glucose
T2 - the Role of Nontraditional Glycemic Markers in Diabetes Diagnosis, Prognosis, and Management
AU - Parrinello, Christina M.
AU - Selvin, Elizabeth
N1 - Funding Information:
Conflict of Interest C.M. Parrinello is supported by NIH/NHLBI Cardiovascular Epidemiology training grant T32HL007024. E. Selvin is supported by NIH/NIDDK grant R01DK089174. The authors thank Dr. David B. Sacks (Department of Laboratory Medicine, National Institutes of Health) for his thoughtful review of a draft of this manuscript.
Publisher Copyright:
© 2014, Springer Science+Business Media New York.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Fasting glucose and hemoglobin A1c (HbA1c) are the standard measures for diagnosis and monitoring of diabetes. There has been recent interest in nontraditional markers of hyperglycemia, including fructosamine, glycated albumin, and 1,5-anhydroglucitol (1,5-AG), as alternatives or adjuncts to standard measures. There is a growing literature linking these nontraditional markers with microvascular and macrovascular complications. Fructosamine and glycated albumin have also been shown to improve identification of persons with diabetes. However, long-term prospective studies with clinical outcomes are lacking. Some modern laboratory assays for fructosamine, glycated albumin, and 1,5-AG have excellent performance. Expanded use of these tests has the potential to improve diabetes care as these measures may overcome limitations of HbA1c in certain patients, complement traditional measures by providing additional information on shorter-term glycemic control, and improve risk stratification for diabetes and its complications. Nonetheless, studies are needed to demonstrate if their routine use will benefit patients and improve outcomes.
AB - Fasting glucose and hemoglobin A1c (HbA1c) are the standard measures for diagnosis and monitoring of diabetes. There has been recent interest in nontraditional markers of hyperglycemia, including fructosamine, glycated albumin, and 1,5-anhydroglucitol (1,5-AG), as alternatives or adjuncts to standard measures. There is a growing literature linking these nontraditional markers with microvascular and macrovascular complications. Fructosamine and glycated albumin have also been shown to improve identification of persons with diabetes. However, long-term prospective studies with clinical outcomes are lacking. Some modern laboratory assays for fructosamine, glycated albumin, and 1,5-AG have excellent performance. Expanded use of these tests has the potential to improve diabetes care as these measures may overcome limitations of HbA1c in certain patients, complement traditional measures by providing additional information on shorter-term glycemic control, and improve risk stratification for diabetes and its complications. Nonetheless, studies are needed to demonstrate if their routine use will benefit patients and improve outcomes.
KW - 1,5-Anhydroglucitol
KW - Biomarkers
KW - Diabetes
KW - Fasting glucose
KW - Fructosamine
KW - Glycated albumin
KW - Hemoglobin A1c
KW - Hyperglycemia
UR - http://www.scopus.com/inward/record.url?scp=84920275110&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920275110&partnerID=8YFLogxK
U2 - 10.1007/s11892-014-0548-3
DO - 10.1007/s11892-014-0548-3
M3 - Review article
C2 - 25249070
AN - SCOPUS:84920275110
SN - 1534-4827
VL - 14
JO - Current diabetes reports
JF - Current diabetes reports
IS - 11
M1 - 548
ER -